BR112013023452A2 - combinação de oligonucleotídeo anti-clusterina com inibidor de hsp90 para o tratamento de câncer de próstata - Google Patents

combinação de oligonucleotídeo anti-clusterina com inibidor de hsp90 para o tratamento de câncer de próstata

Info

Publication number
BR112013023452A2
BR112013023452A2 BR112013023452A BR112013023452A BR112013023452A2 BR 112013023452 A2 BR112013023452 A2 BR 112013023452A2 BR 112013023452 A BR112013023452 A BR 112013023452A BR 112013023452 A BR112013023452 A BR 112013023452A BR 112013023452 A2 BR112013023452 A2 BR 112013023452A2
Authority
BR
Brazil
Prior art keywords
prostate cancer
cancer treatment
hsp90 inhibitor
oligonucleotide combination
clusterin oligonucleotide
Prior art date
Application number
BR112013023452A
Other languages
English (en)
Inventor
Amina Zoubeidi
François Lamoureux
Martin E Gleave
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of BR112013023452A2 publication Critical patent/BR112013023452A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013023452A 2011-03-15 2012-03-12 combinação de oligonucleotídeo anti-clusterina com inibidor de hsp90 para o tratamento de câncer de próstata BR112013023452A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453102P 2011-03-15 2011-03-15
PCT/IB2012/000696 WO2012123823A1 (en) 2011-03-15 2012-03-12 Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
BR112013023452A2 true BR112013023452A2 (pt) 2016-12-06

Family

ID=46830101

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013023452A BR112013023452A2 (pt) 2011-03-15 2012-03-12 combinação de oligonucleotídeo anti-clusterina com inibidor de hsp90 para o tratamento de câncer de próstata

Country Status (13)

Country Link
US (2) US9457045B2 (pt)
EP (1) EP2685990A4 (pt)
JP (1) JP2014509608A (pt)
KR (1) KR20140038388A (pt)
AU (1) AU2012228010B2 (pt)
BR (1) BR112013023452A2 (pt)
CA (1) CA2830195A1 (pt)
IL (1) IL227719A0 (pt)
MX (1) MX2013010524A (pt)
RU (1) RU2013145869A (pt)
SG (1) SG192957A1 (pt)
WO (1) WO2012123823A1 (pt)
ZA (1) ZA201307560B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE385237T1 (de) 1999-02-26 2008-02-15 Univ British Columbia Antisense-therapie für trpm-2
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
KR20140038388A (ko) 2011-03-15 2014-03-28 더 유니버시티 오브 브리티쉬 콜롬비아 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용
US9738643B2 (en) 2012-08-06 2017-08-22 Duke University Substituted indazoles for targeting Hsp90
EP3191473A1 (en) * 2014-09-11 2017-07-19 Esanex, Inc. Indazolyl- and indolyl-benzamide derivatives
WO2017184956A1 (en) * 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
WO2023023189A2 (en) * 2021-08-17 2023-02-23 University Of Virginia Patent Foundation Clusterin overexpression in alzheimer's disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
ATE385237T1 (de) 1999-02-26 2008-02-15 Univ British Columbia Antisense-therapie für trpm-2
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
JP4620585B2 (ja) 2002-08-21 2011-01-26 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア クラステリンレベルを減少させることによる黒色腫の治療
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
CA2584646C (en) 2004-11-23 2015-11-03 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
AR054186A1 (es) 2005-02-25 2007-06-06 Serenex Inc Derivados de tetrahidroindazolona y tetrahidroindolona
WO2006124904A2 (en) * 2005-05-16 2006-11-23 Geron Corporation Cancer treatment by combined inhibition of telomerase and hsp90 activities
WO2011060328A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20140088178A1 (en) 2011-03-14 2014-03-27 The University Of British Columbia Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer
KR20140038388A (ko) 2011-03-15 2014-03-28 더 유니버시티 오브 브리티쉬 콜롬비아 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용
JP2014520081A (ja) 2011-05-19 2014-08-21 テバ ファーマシューティカル インダストリーズ リミティド 非小細胞肺癌を処置するための方法
UY34812A (es) 2012-05-18 2013-12-31 Teva Pharma Método para el tratamiento del cáncer de pulmón de células no pequeñas

Also Published As

Publication number Publication date
AU2012228010A1 (en) 2013-10-31
IL227719A0 (en) 2013-09-30
EP2685990A4 (en) 2014-09-17
RU2013145869A (ru) 2015-04-20
NZ616474A (en) 2015-06-26
JP2014509608A (ja) 2014-04-21
US20140080895A1 (en) 2014-03-20
CA2830195A1 (en) 2012-09-20
US20170145418A1 (en) 2017-05-25
AU2012228010B2 (en) 2016-08-25
WO2012123823A1 (en) 2012-09-20
MX2013010524A (es) 2013-12-06
EP2685990A1 (en) 2014-01-22
SG192957A1 (en) 2013-09-30
KR20140038388A (ko) 2014-03-28
US9457045B2 (en) 2016-10-04
ZA201307560B (en) 2015-06-24

Similar Documents

Publication Publication Date Title
BR112014009755A2 (pt) tratamento de câncer com inibidores de quinase tor
DK2707030T3 (da) Cancerbehandlinger
HK1213444A1 (zh) 癌症的治療
HK1243908A1 (zh) 用於***治療的系統
IL232530B (en) A combination of factors for cancer treatment
BR112013021783A2 (pt) sutiã para tratamento com radiação
BRPI0908127A2 (pt) Método para o tratamento do câncer da próstata com degarelix antagonista do gnrh
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
IT1400425B1 (it) Modified snrnas for use in therapy.
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BR112012002797A2 (pt) tratamento de câncer de próstata
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI1009919A2 (pt) combinações de pentamidina para tratamento de câncer.
BR112013033974A2 (pt) terapia de combinação
DK2760886T3 (da) Immunocytokin-kombinationsterapi
BR112013023452A2 (pt) combinação de oligonucleotídeo anti-clusterina com inibidor de hsp90 para o tratamento de câncer de próstata
FI20115876A0 (fi) Yhdistelmähoito
BR112013011659A2 (pt) métodos de tratamento do câncer
BRPI0922884A2 (pt) compostos para tratamento de câncer
IL227718A0 (en) Combined treatment for prostate cancer using oligonucleotides against clusterin and androgen receptor antagonists
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
BR112014000021A2 (pt) terapia direcionada para egfr
BR112013028890A2 (pt) composições e métodos para o tratamento de câncer
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]